Chronic rhinosinusitis with nasal polyps increases the likelihood of developing coexisting conditions, such as asthma, underscoring the need for more effective, comprehensive treatments.

Patients with severe asthma who initiate biologics may reduce their risk for oral corticosteroids (OCS)-related new-onset adverse outcomes.

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA).

“When they go in and out, back and forth, the temperature shifts cause some problems as well, and then that adds to the ...

GSK’s follow-up to severe asthma therapy Nucala, depemokimab, clears two phase 3 trials, reducing attacks compared to placebo with six-monthly dosing.